SUBSCRIBE: Print / eNewsletter
MM-302 Shows Promise in Heavily Pretreated HER2-Positive Breast Cancer
MM-302 showed encouraging efficacy results and a manageable safety profile in heavily pretreated HER2-positive metastatic breast cancer patients.
First-Line Option Clear in Sequencing of HER2-Positive Breast Cancer Treatments
As more treatment options become available for metastatic HER2-positive breast cancer, some questions regarding the optimal sequencing of therapies remain.
Adding Bevacizumab to Endocrine Therapy No Help in Advanced Breast Cancer
The addition of bevacizumab to endocrine therapy did not prolong survival in postmenopausal women with advanced HER2-negative, HR–positive breast cancer.
FDA Approves Palbociclib for Advanced Breast Cancer
The FDA has approved the CDK4/6 inhibitor palbociclib (Ibrance) for the treatment of postmenopausal women with metastatic breast cancer.
Breast Cancer Patients Often Don't Know Details of Their Tumor
Many women with breast cancer do not understand the details of their tumor characteristics or how they relate to specific treatment options, according to a new study.
PIK3CA Mutations Matter in HER2-Positive Breast Cancer
Two recently published studies suggest that PIK3CA mutations cannot be used as a predictive biomarker to guide therapy in HER2-positive breast cancer.
Preventive Tamoxifen Lowers Rate of ER-Positive Breast Cancer
Tamoxifen given to women at high risk for breast cancer lowered the rate of estrogen receptor (ER)-positive breast cancer diagnosis in the IBIS-I trial.
Fulvestrant Improved Survival in First-Line Advanced Breast Cancer
Fulvestrant improved overall survival compared with anastrozole, among women with treatment-naive, advanced, hormone receptor-positive breast cancer.
Avastin May Benefit Basal-Like Breast Cancer Patients
A study of triple-negative breast cancer patients found that adding bevacizumab to chemo resulted in higher pCR rates in those with basal-like disease.
Immunotherapy Yields Response in Triple-Negative Breast Cancer
The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.